首頁 › 非霍奇金淋巴瘤 › 德克薩斯州 › Houston
Houston, TX 的 非霍奇金淋巴瘤 臨床試驗
31 項針對 非霍奇金淋巴瘤 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Md Anderson Cancer Center, Houston
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
招募中1 期
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
招募中1 期
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
招募中1 期
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
招募中觀察性研究
- Texas Children's Hospital, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Baylor College of Medicine, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- Md Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
招募中1/2 期
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
招募中2 期
- Research Site, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
招募中1 期
- Clinical Trial Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
招募中2 期
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
招募中1 期
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- 還有 1 項
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
招募中2 期
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- MD Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
招募中1 期
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
招募中1 期
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
招募中2 期
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
招募中1 期
- MD Anderson Cancer Center, Houston
其他城市的 非霍奇金淋巴瘤 試驗
- New York City, NY31 項研究
- Boston, MA26 項研究
- Nashville, TN21 項研究
- Philadelphia, PA20 項研究
- Baldwin Park, CA19 項研究
- Washington, DC18 項研究
- Chicago, IL18 項研究
- Milwaukee, WI18 項研究
- Atlanta, GA18 項研究
- Columbus, OH18 項研究
- Dallas, TX17 項研究
- Seattle, WA16 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。